ReviewHematology/oncology clinics of North America2019
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Review in Hematology/oncology clinics of North America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Review
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma.Nature communications · 2025Article
- SurvDB: Systematic Identification of Potential Prognostic Biomarkers in 33 Cancer Types.International journal of molecular sciences · 2025Article
- Is programmed death-ligand 1 positivity a predictor of poor survival in patients with different histological subtypes of pancreatic cancer?CytoJournal · 2025Article
- Cancer and the Microbiome of the Human Body.Nutrients · 2024Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Clinical Proteomics for Solid Organ Tissues.Molecular & cellular proteomics : MCP · 2023Article
- Expression of β-Catenin, E-Cadherin, and α-Smooth Muscle Actin in Basal Cell Carcinoma Before Photodynamic Therapy in Non-recurrent and Recurrent Tumors: Exploring the Ability of Predicting Photodynamic Therapy Outcome.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2023Article
- Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine.Current oncology (Toronto, Ont.) · 2023Review
- Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.World journal of surgical oncology · 2023Article
- Effect of the preoperative prognostic nutritional index on the long-term prognosis in patients with borderline resectable pancreatic cancer after pancreaticoduodenectomy.Frontiers in oncology · 2023Article
- An update on methods for detection of prognostic and predictive biomarkers in melanoma.Frontiers in cell and developmental biology · 2023Review
- Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.Biomedicines · 2022Article
- Promoting Best Practice in Cancer Care in Sub Saharan Africa.Frontiers in medicine · 2022Article
- Review
- PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma.Translational cancer research · 2021Article
- Electrochemical biosensors for measurement of colorectal cancer biomarkers.Analytical and bioanalytical chemistry · 2021Review
- RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype.Biomedicines · 2020Article
- Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.American journal of clinical dermatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.